Hypophosphatasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hypophosphatasia markets reached a value of US$ 725.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,036.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.3% during 2024-2034.
The hypophosphatasia market has been comprehensively analyzed in IMARC's new report titled "Hypophosphatasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypophosphatasia (HPP) refers to a rare, inherited metabolic disorder characterized by decreased activity of the tissue-nonspecific alkaline phosphatase enzyme, resulting in impaired mineralization of bones and teeth. This condition affects people of all ages, but its severity varies widely, ranging from mild to life-threatening. The symptoms of the ailment primarily manifest in the skeletal system and can include weak and soft bones, fractures, stunted growth, and dental problems. Infants suffering from severe HPP may experience respiratory issues due to underdeveloped ribcages, while adults may suffer from recurrent fractures and early tooth loss. Numerous other features may include muscle weakness, joint pain, delayed motor development, etc. The diagnosis of the illness can be challenging due to its diverse clinical presentations and rarity. A thorough clinical evaluation, including a detailed medical history, physical examination, and assessment of biochemical markers, is recommended. Additionally, X-rays, genetic testing, and bone biopsies may aid in confirming the diagnosis among patients.
The escalating prevalence of somatic mutations in genetic materials, which can result in impaired bone mineralization and abnormal tooth development, is primarily driving the hypophosphatasia market. In addition to this, the inflating utilization of effective treatments, such as enzyme replacement therapy and bone-targeted therapies, like asfotase alfa, to manage and alleviate the symptoms of the disease is also creating a positive outlook for the market. These therapies help to improve bone mineralization and skeletal growth, enhancing the quality of life for individuals suffering from the ailment. Moreover, the growing adoption of physical and occupational therapies, since they work by strengthening muscles, promoting mobility, and encouraging gross motor skills to reduce some of the challenges associated with the disorder, is further bolstering the market growth. Apart from this, the increasing awareness of the condition, along with advancements in medical research activities to launch novel drugs and improve outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatments like gene therapy, which holds promise for correcting the genetic defects responsible for the disease, thereby potentially offering a curative approach and transforming the treatment landscape for HPP, is expected to drive the hypophosphatasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypophosphatasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypophosphatasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypophosphatasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypophosphatasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypophosphatasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypophosphatasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypophosphatasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypophosphatasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypophosphatasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypophosphatasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypophosphatasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypophosphatasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypophosphatasia across the seven major markets?
What is the size of the hypophosphatasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypophosphatasia?
What will be the growth rate of patients across the seven major markets?
Hypophosphatasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypophosphatasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypophosphatasia market?
What are the key regulatory events related to the hypophosphatasia market?
What is the structure of clinical trial landscape by status related to the hypophosphatasia market?
What is the structure of clinical trial landscape by phase related to the hypophosphatasia market?
What is the structure of clinical trial landscape by route of administration related to the hypophosphatasia market?
The hypophosphatasia market has been comprehensively analyzed in IMARC's new report titled "Hypophosphatasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypophosphatasia (HPP) refers to a rare, inherited metabolic disorder characterized by decreased activity of the tissue-nonspecific alkaline phosphatase enzyme, resulting in impaired mineralization of bones and teeth. This condition affects people of all ages, but its severity varies widely, ranging from mild to life-threatening. The symptoms of the ailment primarily manifest in the skeletal system and can include weak and soft bones, fractures, stunted growth, and dental problems. Infants suffering from severe HPP may experience respiratory issues due to underdeveloped ribcages, while adults may suffer from recurrent fractures and early tooth loss. Numerous other features may include muscle weakness, joint pain, delayed motor development, etc. The diagnosis of the illness can be challenging due to its diverse clinical presentations and rarity. A thorough clinical evaluation, including a detailed medical history, physical examination, and assessment of biochemical markers, is recommended. Additionally, X-rays, genetic testing, and bone biopsies may aid in confirming the diagnosis among patients.
The escalating prevalence of somatic mutations in genetic materials, which can result in impaired bone mineralization and abnormal tooth development, is primarily driving the hypophosphatasia market. In addition to this, the inflating utilization of effective treatments, such as enzyme replacement therapy and bone-targeted therapies, like asfotase alfa, to manage and alleviate the symptoms of the disease is also creating a positive outlook for the market. These therapies help to improve bone mineralization and skeletal growth, enhancing the quality of life for individuals suffering from the ailment. Moreover, the growing adoption of physical and occupational therapies, since they work by strengthening muscles, promoting mobility, and encouraging gross motor skills to reduce some of the challenges associated with the disorder, is further bolstering the market growth. Apart from this, the increasing awareness of the condition, along with advancements in medical research activities to launch novel drugs and improve outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatments like gene therapy, which holds promise for correcting the genetic defects responsible for the disease, thereby potentially offering a curative approach and transforming the treatment landscape for HPP, is expected to drive the hypophosphatasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypophosphatasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypophosphatasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypophosphatasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypophosphatasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypophosphatasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypophosphatasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hypophosphatasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypophosphatasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypophosphatasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypophosphatasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypophosphatasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypophosphatasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypophosphatasia across the seven major markets?
What is the size of the hypophosphatasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypophosphatasia?
What will be the growth rate of patients across the seven major markets?
Hypophosphatasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypophosphatasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypophosphatasia market?
What are the key regulatory events related to the hypophosphatasia market?
What is the structure of clinical trial landscape by status related to the hypophosphatasia market?
What is the structure of clinical trial landscape by phase related to the hypophosphatasia market?
What is the structure of clinical trial landscape by route of administration related to the hypophosphatasia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPOPHOSPHATASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPOPHOSPHATASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPOPHOSPHATASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPOPHOSPHATASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPOPHOSPHATASIA - UNMET NEEDS
10 HYPOPHOSPHATASIA - KEY ENDPOINTS OF TREATMENT
11 HYPOPHOSPHATASIA - MARKETED PRODUCTS
11.1 List of Hypophosphatasia Marketed Drugs Across the Top 7 Markets
11.1.1 Strensiq (Asfotase alfa) - Alexion AstraZeneca Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPOPHOSPHATASIA - PIPELINE DRUGS
12.1 List of Hypophosphatasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Ilofotase alfa - AM-Pharma Holding
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ALXN 1850 - Alexion Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPOPHOSPHATASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPOPHOSPHATASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPOPHOSPHATASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypophosphatasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypophosphatasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypophosphatasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypophosphatasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypophosphatasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypophosphatasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypophosphatasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypophosphatasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypophosphatasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypophosphatasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypophosphatasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypophosphatasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypophosphatasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypophosphatasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypophosphatasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypophosphatasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypophosphatasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypophosphatasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypophosphatasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypophosphatasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypophosphatasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypophosphatasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypophosphatasia - Access and Reimbursement Overview
16 HYPOPHOSPHATASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPOPHOSPHATASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPOPHOSPHATASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPOPHOSPHATASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPOPHOSPHATASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPOPHOSPHATASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HYPOPHOSPHATASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPOPHOSPHATASIA - UNMET NEEDS
10 HYPOPHOSPHATASIA - KEY ENDPOINTS OF TREATMENT
11 HYPOPHOSPHATASIA - MARKETED PRODUCTS
11.1 List of Hypophosphatasia Marketed Drugs Across the Top 7 Markets
11.1.1 Strensiq (Asfotase alfa) - Alexion AstraZeneca Rare Disease
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPOPHOSPHATASIA - PIPELINE DRUGS
12.1 List of Hypophosphatasia Pipeline Drugs Across the Top 7 Markets
12.1.1 Ilofotase alfa - AM-Pharma Holding
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ALXN 1850 - Alexion Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HYPOPHOSPHATASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPOPHOSPHATASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPOPHOSPHATASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypophosphatasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypophosphatasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypophosphatasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypophosphatasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypophosphatasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypophosphatasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypophosphatasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypophosphatasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypophosphatasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypophosphatasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypophosphatasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypophosphatasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypophosphatasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypophosphatasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypophosphatasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypophosphatasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypophosphatasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypophosphatasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypophosphatasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypophosphatasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypophosphatasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypophosphatasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypophosphatasia - Access and Reimbursement Overview
16 HYPOPHOSPHATASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPOPHOSPHATASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPOPHOSPHATASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
